Systemic scleroderma: Clinical and pathophysiologic aspects

Journal of the American Academy of Dermatology

Volumn 18, Issue 3, 1988, Pages 457-481

  Krieg, Thomas ^a   Meurer, Michael ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CAPTOPRIL; CYCLOFENIL; CYCLOSPORIN A; GAMMA INTERFERON; KETANSERIN; NIFEDIPINE; PENICILLAMINE; PLASMA SUBSTITUTE; PREDNISOLONE; PROLINE; PROSTACYCLIN;

ARTHRITIS; CLASSIFICATION; FIBROSIS; HUMAN; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS;

EID: 0023874792     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(88)70070-5     Document Type: Article

References (161)

1. An account of an extraordinary disease of the skin and its cure
2. Note sur la sclerodermie
3. The visceral manifestations of scleroderma
4. A historical account of the study of progressive systemic sclerosis (diffuse scleroderma)
5. Systemic scleroderma. A clinical study of 727 cases
6. Epidemiology of progressive systemicsclerosis
7. Survival in systemic sclerosis (scleroderma)
8. The epidemiology of systemic sclerosis (scleroderma)
9. Increased frequency of HLA-DR5 in scleroderma
10. Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response
11. Assoziation von HLA-Antigenen und Sklerodermie
12. HLA antigens, autoantibodies and clinical subsets in scleroderma
13. DR antigens in systemic sclerosis: lack of clinical correlations
14. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma)
15. Sclérodermiè géneralisiée et cassures chromosomiques. Mise en évidence d’un “facteur cassant” dans le serum de malades
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Di-agnostic and Therapeutic Criteria Committee
17. Classification and nomenclature of progressive systemic sclerosis (scleroderma)
18. Pathogenesis and staging of scleroderma
19. Vorschlag zu einer neuen Klassifizierung und Nomenklatur der progredienten generalisierten Sklerodermie (PGS)
20. Arbeitsgruppe Sklerodermie der Arbeitsgemeinschaft Dermatologische Forschung (ADF). Klinik der progressiven systemischen Sklerodermie (PSS)
21. Einteilung und Klinik der progressiven systemischen Sklerodermie (PSS)
22. Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly and subcutaneous calcinosis; a syndrome mimicking hereditary hemorrhagic telangiectasia
23. The CREST syndrome. Comparison with the systemic sclerosis (scleroderma)
24. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy. A prospective study of patients with Raynaud phenomerion
25. Une forme de concrètions calcaires sous cutanées en relation avec la sclèrodermié
26. Scleroderma and the subcutaneous tissue
27. Immu-nofluorescence analysis of collagen, fibronectin and basement membrane protein in scleroderma skin
28. Collagen flbrils of the scleroderma in ultrathin sections
29. Manometric assessment of oesophageal involvement in progressive systemic sclerosis, morphea and Raynaud's disease
30. Early changes in oesophageal function in progressive systemic sclerosis: a comparison of manometry and radiology
31. Assessment of esophageal abnormalities in progressive systemic sclerosis using radionuclide transit
32. Radionuclide esophageal transit in progressive systemic sclerosis
33. Barrett's esophagus complicating scleroderma
34. Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: is increased patient screening necessary?
35. Comparative esophageal and anorectal motility in scleroderma
36. The gastrointestinal manifestations of scleroderma: pathogenesis and management [clinical conference]
37. Steatorrhoea in progressive systemic sclerosis (scleroderma)
38. Small intestinal bacterial growth in systemic sclerosis
39. Gastrointestinal telangiectasia as a cause of severe blood loss in systemic sclerosis
40. Bleeding gastric telangiectasia. Complication of Raynaud's phenomenon, esophageal motor dysfunction, sclerodactyly and telangiectasia (REST) syndrome
41. Chronic disease of the Iiver associated with systemic scleroderma
42. Idiopathic portal hypertension associated with progressive systemic sclerosis
43. Rheumatic disorders in primary biliary cirrho-sis
44. Anti-centromere antibodies in primary biliary cirrhosis
45. Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathologie features, pathogenesis, and new therapeutic approaches
46. The heart in scleroderma: noninvasive assessment
47. The relationship of arrhythmias and conduction disturbances to other manifestations of car-diopulmonary disease in progressive systemic sclerosis (PSS)
48. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma
49. Decreased coronary reserve in primary scleroderma myocardial disease
50. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature
51. Pulmonary insufficiency. II. A study of thirty-nine cases of pulmonary ftbrosis
52. Scleroderma of the lungs
53. Lung involvement in scleroderma
54. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis
55. Small airways in progressive systemic sclerosis (PSS)
56. Pulmonary involvement in systemic sclerosis (scleroderma)
57. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis
58. Renal involvement in progressive systemic sclerosis (scleroderma)
59. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis Review of a 25-year experience with 68 cases
60. The kidney in progressive systemic sclerosis
61. The kidney in progressive systemic sclerosis: immunohistochemical and antibody elution studies
62. The nature of joint involvement in progressive systemic sclerosis (scleroderma). Clinical study and pathologie examination of synovium in 29 patients
63. The articular manifestations of progressive systemic sclerosis (scleroderma)
64. Jaccoud's arthropathy in scleroderma
65. The joint manifestations of the connective tissue diseases
66. The arthropathy of systemic sclerosis (scleroderma); comparison with mixed connective tissue disease
67. The nature of skeletal muscle involvement in progressive systemic sclerosis (scleroderma)
68. Sjögren's syndrome in progressive systemic sclerosis (scleroderma)
69. Clinical and serologic study of Sjögren's syndrome in patients with progressive systemic sclerosis
70. Electromyographic findings in various forms of progressive systemic sclerosis
71. Diversity of antinuclear antibodies in progressive systemic sclerosis
72. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis
73. Antinucleolar antibodies in human sera
74. Detection of a nucleolar 7–2 ribonucleoprotein and a cytoplasmatic 8–2 ribonucleoprotein with autoantibodies from patients with scleroderma
75. Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34.000; pl. 8.5) rich in NG, NG-dimethylarginine
76. Autoantibody to RNA-polymerase I in scleroderma sera
77. Immunolocal-ization and partial molecular characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes
78. Antinuclear antibody with distinct specificity for polymyositis
79. Autoantibody to centromere (kinetochore) in scleroderma sera
80. Kinetochore structure, duplication and distribution in mammalian cells. Analysis by human autoantibodies from scleroderma patients
81. Human anticentromere antibodies: distribution, characterization of anti-gens and effect on microtubule organization
82. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies
83. Anticentromere and anticentriole antibodies in the scleroderma spectrum
84. Zentromerantikörper und Antikörper gegen Scl-70-Nucleoprotein bei progressiver systemischer Sklerodermie
85. Clinical and laboratory associations of anticentromere antibodies in patients with progressive systemic sclerosis
86. The CREST syndrome: a distinct serologic entity with anticentromere antibodies
87. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis
88. Anticentromere antibodies in primary biliary cirrhosis
89. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap
90. Identification of a nuclear protein (Scl 70) as a unique target of human antinuclear antibodies in scleroderma
91. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients
92. Scl-70 autoantibodies from scleroderma patients recognize a 95 kD protein-identified as DNA topoisomerase I
93. Skin capillary changes in early systemic scleroderma
94. Structure, development, and molecular pathology of basement membranes
95. Antibodies to collagen in scleroderma
96. Endothelial injury in scleroderma—a protease mechanism
97. Endothelial injury in scleroderma
98. Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture
99. Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity
100. Enhanced platelet adhesion to collagen in scleroderma. Effect of scleroderma plasma and scleroderma platelets
101. Polypeptide transforming growth factor isolated from bovine sources and used for wound healing in vivo
102. Transforming growth factor β: rapid induction of flbrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
103. Lymphocyte subpopulations and reactivity to mitogens in patients with scleroderma
104. Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis
105. Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies
106. Autologous and allogeneic mixed lymphocyte reactions in progressive systemic sclerosis
107. Decreased autologous mixed lymphocyte reaction (AMLR) in progressive systemic scleroderma (PSS)
108. Abnormalities of T lymphocyte subsets in patients with progressive systemic sclerosis (PSS scleroderma)
109. Lymphokine stimulation of collagen accumulation
110. Lymphocyte-mediated activation of fibroblast proliferation and collagen production
111. Soluble mediators from mononuclear cells increase the synthesis of glycosaminoglycan from dermal fibroblast cultures derived from normal subjects and progressive systemic sclerosis patients
112. Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture
113. Inhibition of collagen synthesis by mononuclear cell supernatants
114. Lympho-kine/monokine inhibition of fibroblast proliferation and collagen production: role in progressive systemic sclerosis (PSS)
115. Interleukin 1, a potential regulator of fibroblast proliferation
116. Synthesis of types I, UI and AB2 collagen by chick tendon fibroblasts in vitro
117. Human skin fibroblasts derived from papillary and reticular dermis: differences in growth potential in vitro
118. Vari-ability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture
119. Collagen synthesis by scleroderma fibroblasts
120. Fibroblast selection in scleroderma
121. A fibroblast mitogen present in scleroderma but not control sera: inhibition by proteinase inhibitors
122. Surface proteins of scleroderma fibroblasts in culture
123. Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors
124. Cell movements in wound-healing and fibrosis
125. Glycosaminoglycans in scleroderma and scleredema
126. Connective tissue in scleroderma
127. Immunohisto-chemical demonstration of proteoglycans in the skin of patients with systemic sclerosis
128. The genetically distinct collagens
129. Collagen in the cellular and fibrotic stages of scleroderma
130. Scleroderma: increased biosynthesis of triple-helical type I and type IU procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture
131. Skin collagen content in progressive systemic sclerosis (scleroderma) and localized scleroderma
132. Procollagen proline hydroxylase activity in the skin of normal human subjects and of patients with scleroderma
133. Increased protocollagen proline hydroxylase activity in sclerodermatous skin
134. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma
135. Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma)
136. Collagen synthesis in scleroderma: selection of fibroblast populations during subcultures
137. Increased procollagen mRNA levels in scleroderma skin fibroblasts
138. Activation of type I collagen genes in cultured scleroderma fibroblasts
139. Aminoterminal extension peptides from type I procollagen normalize excessive collagen synthesis of scleroderma fibroblasts
140. Collagen synthesis regulation by the aminopropeptide of procollagen I in normal and scleroderma fibroblasts
141. Posttranslational enzymes in the biosynthesis of collagen: intracellular enzymes
142. Collagen biosynthesis in systemic scleroderma: regulation of posttranslational modifications and synthesis of procollagen in cultured fibroblasts
143. Collagen fibrillogenesis: a mechanism of structural biology
144. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynauďs syndrome
145. The effect of intermittent low molecular dextran infusions upon the digital circulation in systemic sclerosis
146. Nifedipine and Raynaud's phenomenon
147. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon
148. Reversal of vascular and renal crisis of scleroderma by oral angiotensin-converting-enzyme blockade
149. Treatment of Raynauďs phenomenon with 5-HT2-receptor antagonist ketanserin
150. d-Penicillamine therapy in progressive systemic sclerosis: a retrospective analysis
151. Progressive systemic sclerosis. Management. III. Immunosuppressive agents
152. Cyclofenil versus placebo in progressive systemic sclerosis. A one-year doublé blind crossover study of 27 patients
153. Long-term evaluation of colchicine in the treatment of scleroderma
154. Therapeutic activity of factor XIII clotting factor in scleroderma. La Nouvel
155. Treatment of generalized scleroderma with inhibitors of collagen synthesis
156. The 2-oxoglutarate binding site of prolyl-4-hydroxylase
157. Regulation of protein synthesis: translational control byprocollagen derived fragments